This past month, OncoSec’s Chief Medical Officer, Dr. Robert Pierce, participated in the 6th Annual Melanoma Research Alliance Scientific Retreat The conference seeks to advance the field of melanoma research, by providing an interactive forum that facilitates data sharing and discussion among key field leaders. This is accomplished through guest participation in a series of collaborative and thought-provoking activities, including panel discussions and notable speaker presentations.
We’ve had a busy year at OncoSec. From our ongoing clinical trials to the formation of our melanoma board, research agreement with Old Dominion University and in between, the last year has moved us deeper into cancer research and engaging with patient communities. As we have only a matter of days left in 2013, we would like to look back at this year in review. Here is a selection of some of our activities this year:
The holiday season around Christmas is a time to spend with family and loved ones. It’s a part of the year where many people set aside their differences and celebrate each other and their lives. Christmas can be a difficult time for cancer patients, along with many survivors: they can be stuck in the hospital, under quarantine, away from their loved ones, or bending under the weight of harsh side effect management. We would like to take a moment to show our appreciation for cancer advocates and survivors who have brought joy and laughter to those who have suffered from cancer:
In the past, we have talked about a number of carcinogens and other cancer causing agents. From UV rays to cigarette smoking and food additives, there are many factors that can increase cancer risk among different individuals. While, in some cases, it can be unclear exactly how certain carcinogenic materials cause cancer, correlations have been drawn time and time again between many of them. One advanced form of risk assessment for cancer is that of genetics. In fact, we each carry different genetic risk factors determined by heredity and gene mutations.
With our ongoing series on immunotherapy and comparisons between various cancer treatment techniques, it is important to see what it is that different therapies do to the human body. In the field of cancer research, there are many types of treatment that are currently used. Today, we examine what radiation therapy and several variations of targeted therapy and immunotherapy do, in order to discuss the effects of cancer treatment on the body:
In our ongoing attempt to get our community better acquainted with what we do at OncoSec, we’ve been creating more dialogue around our ImmunoPulse program and recent clinical trial data. With the expanding biotech landscape, we find it important to educate the public about topics of interest that are directly impacting the way medicine is being researched and treatment options created. The field of immunotherapy is one of these fields on the cutting edge of medical advancements. Here we’ve compiled a list of four frequently asked questions about immunotherapy:
While the iconic pink ribbon has represented breast cancer awareness and support for quite some time, male cancers – and men’s health in general – can often be overlooked. With cultural stigma in many societies surrounding men seeking medical attention as a sign of weakness, men often avoid visits to the doctor. In an attempt to raise awareness and funding for men’s health, two Australians inadvertently created one of the most dominant non-profit organizations in the world, around this very topic: Movember.
Immunotherapy is the vein of medicine and biotechnology that uses the human immune system in fighting disease. This is done through stimulating, signaling or otherwise manipulating the cells of the immune system to more effectively locate and destroy foreign cells. With some obvious differences from more traditional treatment methods, immunotherapy techniques attempt to use smaller dosages of drugs, while maximizing effectiveness. One of the important agents currently being researched for use in immunotherapy is interleukin-12 (or IL-12).
Recently, we filmed a clinical progress video discussing details of our ImmunoPulse therapy and results with Tu Diep: OncoSec’s executive director of clinical development. With over a decade of experience in clinical research, prior to joining OncoSec – including Protox Therapeutics Inc. (now Sophiris Bio Inc.) – Mr. Diep’s experience has been a large asset to our company.